News

Number of submitted proposals for ERC Proof of Concept Grant 2024 call – 2nd cut-off deadline 17 September 2024

Published on | 1 year ago

Programmes ERC

A total of 399 proposals were submitted in response to the second and final deadline (17 September 2024) of the ERC 2024 Proof of Concept Call. In total, this represents 20% more PoC proposals to the 2024 call (728) than to the three deadlines of the 2023 call (608 proposals).

Evaluation results are expected to be communicated in January 2025.

The ERC-2025-PoC call will be published on 13 November 2024 and open for submission on the Funding & Tender opportunities Portal, with 2 cut-off dates (deadlines): 13 March 2025 and 18 September 2025 (17:00:00 time zone Brussels time).

Source: European Commission Funding and Tenders Portal

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1772 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.